Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes

Summary

Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects and in subjects with obesity and Type 2 diabetes.

Timeline

Start

2023-06-13

Primary completion

2024-08-12

Completion

2024-08-12

Drugs

Indications